Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14524914 | 0.86 | AR (0.44) | ARCYP11B2KIF11KDM1AMMP3 | |
| SCHEMBL14524884 | 0.81 | FFAR1 (0.41) | ARCYP11B2KDM1ANSD2PDE3B | |
| SCHEMBL14525145 | 0.78 | PDE3B (0.37) | ARKIF11PTGS1KDM1AMMP3 | |
| SCHEMBL19579048 | 0.78 | KIF11 (0.52) | ARCYP11B2KIF11PTGS1MMP3 | |
| SCHEMBL3997043 | 0.78 | MMP3 (0.46) | ARCYP11B2KIF11MMP3ALDH1A1 | |
| SCHEMBL16941052 | 0.77 | KIF11 (0.43) | CYP11B2KIF11PTGS1KDM1ANSD2 | |
| SCHEMBL19579265 | 0.76 | KIF11 (0.50) | ARCYP11B2KIF11PTGS1MMP3 | |
| SCHEMBL14499519 | 0.76 | KDM1A (0.42) | ARCYP11B2KIF11PTGS1KDM1A | |
| SCHEMBL8021406 | 0.74 | KIF11 (0.54) | CYP11B2KIF11PTGS1MMP3PDE3B | |
| SCHEMBL14524967 | 0.74 | CYP11B2 (0.40) | ARCYP11B2KIF11PTGS1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | AR 31/4885CYP11B2 1846/4885KIF11 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.